COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

A Phase I Study of MR-Guided Dose-Escalated Hypofractionated Adaptive Radiation Therapy and Immunotherapy in Primary Metastatic or Very Locally Advanced Patients with Head and Neck Cancer

Protocol No
IIT-AWAN-NIH-DEHART
Principal Investigator
Musaddiq Awan
Phase
I
Summary
The purpose of this study is to test an experimental treatment for your HNSCC. This study will use a new way of administering radiation therapy for HNSCC called Magnetic Resonance-guided Radiation Therapy (MRgRT), MRgRT uses weekly MRI scans to track how your cancer changes over the course of treatment. This makes it possible to increase the dose of radiation given to specific areas that need it while reducing the dose of radiation given to specific areas where the tumor is getting smaller. Subjects in this study will also receive the immunotherapy drug Atezolizumab during and after radiation therapy. Researchers hope that this treatment plan will result in better outcomes and fewer adverse effects compared to standard radiation therapy. This treatment is investigational, meaning it has not been approved by the FDA for the treatment of your cancer. We don't know if this study will help you. Your condition may get better but it could stay the same or even get worse. We hope the information from this study will help us develop better treatments for head and neck cancer.
Description
A Phase I Study of MR-Guided Dose-Escalated Hypofractionated Adaptive Radiation Therapy and Immunotherapy in Primary Metastatic or Very Locally Advanced Patients with Head and Neck Cancer
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Sub Category